This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Acetylcholinesterase inhibitor treatment is associated with relatively slow cognitive decline in patients with Alzheimer’s disease and AD + DLB


Nelson, Peter T., Kryscio, Richard J., Abner, Erin L., Schmitt, Frederick A., Jicha, Gregory A., Mendiondo, Marta S., Cooper, Greg, Smith, Charles B., Markesbery, William R.


Journal of Alzheimer's Disease, Volume: 16, No.: 1, Pages.: 29-34

Year of Publication



Dementia can be caused by different diseases including Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), or both (AD + DLB). University of Kentucky AD Center pathologically-diagnosed AD and AD + DLB cases were evaluated who had three or more longitudinal antemortem mental status examinations (n = 156). Patients with important concomitant pathology (n = 5) or patients that were profoundly demented at recruitment (intake MMSE < 20; n = 86) were excluded to strengthen our ability to test the association of specific clinical and pathological indices. Patients with pathologically-diagnosed AD + DLB (n = 25) lost cognitive capacity faster than patients with AD alone (n = 40). In both diseases, treatment with acetylcholinesterase inhibitors was associated with a slower rate of cognitive decline. (PsycINFO Database Record (c) 2012 APA, all rights reserved). (journal abstract)


acetylcholinesterase, acetylcholinesterase inhibitor treatment, alzheimer’s disease, cognitive impairment, dementia with lewy bodies, drug therapy, enzyme inhibitors, inhibitors, patients, slow cognitive decline

Countries of Study


Types of Dementia

Alzheimer’s Disease, Lewy-Body

Types of Study

Cohort Study

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime